The pivotal phase 3 PIVOT-PO clinical trial (NCT06059846) evaluating tebipenem pivoxil hydrobromide (Tebipenem HBr; Spero Therapeutics and GSK), an investigational treatment for complicated urinary tract infections (cUTIs), met its primary end point and stopped early for efficacy, according to a news release. This decision was reported to have followed a recommendation from an Independent Data Monitoring Committee (IDMC).1,2
About the Trial
Trial Name: A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (PIVOT-PO)
ClinicalTrials.gov ID: NCT06059846
Sponsor: Spero Therapeutics
Completion Date: November 2025
“Achieving the primary end point in the PIVOT-PO trial marks a significant milestone for [tebipenem pivoxil hydrobromide]. If approved, we believe [tebipenem pivoxil hydrobromide] is well positioned to change the treatment landscape for patients diagnosed with cUTI, including pyelonephritis,” Esther Rajavelu, CEO of Spero Therapeutics, said in the news release.1
Tebipenem pivoxil hydrobromide is a late-stage agent under development for the treatment of cUTIs, including pyelonephritis, that are caused by certain bacteria. It is an oral formulation of tebipenem pivoxil, which is a carbapenem antibiotic of the β-lactam class. Previously, it received qualified infectious disease product and fast track designations from the FDA.1,3
cUTIs are broadly described as any UTI that carries an increased risk of either morbidity or mortality. Currently, definitions among international societies and regulatory agencies are not uniform. The infection encompasses a heterogeneous patient population because of the wide range of host factors, comorbidities, and urological abnormalities associated with cUTIs. Risk factors for cUTI include the following: indwelling catheters, ureteric stents, neurogenic bladder, obstructive uropathy, urinary retention, urinary diversion, kidney stones, diabetes, immune deficiency, urinary tract modification, and UTIs in patients following renal transplant.1
PIVOT-PO is a global, randomized, double-blind, double-dummy, multicenter, multinational phase 3 clinical trial assessing the efficacy of oral tebipenem pivoxil hydrobromide in hospitalized adult patients with cUTI, including pyelonephritis. A total of 1690 patients were randomly assigned to receive either 600 mg of oral tebipenem pivoxil hydrobromide and an intravenous (IV) dummy infusion (0.9% sodium chloride), or 500 mg of imipenem-cilastatin and matched oral dummy tablets. Both regimens were administered every 6 hours from days 1 through 10. Randomization was reported to be stratified by age, baseline diagnosis, and the presence or absence of urinary tract instrumentation.1,2